GlassScriptPhysician profile
Charles A Shapiro
NPI 1881600948
$12,967.32
in general payments reported to CMS, 2019-2025
24 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,321 · 2020: $2,243 · 2021: $1,655 · 2022: $1,690 · 2023: $2,131 · 2024: $1,823 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,857 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,857.40 |
| Education | $200.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,217.68 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,986.13 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Optinose US, INC. | $1,321.68 | 2019-2025 | |
| Genzyme Corporation | $1,220.40 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $830.07 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.15 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Combivent Respimat |
| Novartis Pharmaceuticals Corporation | $618.69 | 2019-2025 | |
| Amgen INC. | $568.24 | 2022-2025 | Tezspire |
| Pfizer INC. | $275.55 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $267.98 | 2022-2025 | |
| Genentech USA, INC. | $157.31 | 2019-2022 | |
| Alk-Abello, INC | $132.31 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Greer Laboratories, INC. | $110.54 | 2019 | |
| Kaleo, INC. | $106.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $98.72 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $97.78 | 2025 | Neffy |
| Pharming Healthcare, INC. | $60.92 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $54.85 | 2021-2022 | |
| Incyte Corporation | $40.47 | 2021-2022 | |
| Uswm, LLC | $40.00 | 2021 | |
| Circassia INC. | $35.84 | 2019 | |
| Abbvie INC. | $21.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.